- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01873495
Omacetaxine for Consolidation and Maintenance
September 5, 2019 updated by: Martha Arellano, Emory University
Omacetaxine for Consolidation and Maintenance in Patients Age ≥ 55 With AML in First Remission: A Pilot Study
The purpose of this pilot study is to assess the safety and tolerability of omacetaxine for consolidation in patients age 55 and older with acute myelogenous leukemia (AML) in first complete remission following induction with cytarabine and an anthracycline, and also to assess the safety and tolerability of omacetaxine for maintenance in patients age 55 and older with acute AML in first complete remission following 3 consolidation courses with omacetaxine.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
7
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University Winship Cancer Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
55 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosis of AML including de novo, secondary, or with an antecedent hematologic disorder (AHD) according to the World Health Organization (WHO) criteria.
- Age ≥ 55 years.
- Patient eligible for standard induction chemotherapy based on Eastern Cooperative Oncology Group (ECOG) performance status and vital organ function at the discretion of the treating physician.
- Patients who received 1-2 cycles of hypomethylating therapy (decitabine azacitidine) are eligible.
- Provide signed written informed consent.
- Be able to comply with study procedures and follow-up examinations.
- Be non-fertile or agree to use birth control during the study through the end of last treatment visit.
Adequate renal and hepatic function at the time of second registration:
- Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN); and
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN; and
- Serum creatinine ≤ 1.2 x ULN.
- ECOG performance ≤ 2 at the time of second registration.
- Patients with a history of carcinoma in remission, on no therapy or on hormonal therapy for the adjuvant treatment of breast carcinoma or prostate carcinoma are included in the study.
Exclusion Criteria:
- Diagnosis of acute promyelocytic leukemia (APL, French-American-British [FAB] classification M3 or WHO classification of APL with t (15;17)(q22;q12), (PML/retinoic acid receptor alpha [RARa] and variants).
- Prior treatment with omacetaxine.
- Relapsed or refractory AML.
- Investigational agent received within 30 days prior to the first dose of study drug. If received any investigational agent prior to this time point, drug-related toxicities must have recovered to Grade 2 or less prior to first dose of study drug.
- Psychiatric disorders that would interfere with consent, study participation, or follow-up.
- Systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment).
- Any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system that may place the patient at undue risk to undergo the proposed therapy. This includes uncontrolled hypertension and uncontrolled diabetes, as cases of life threatening hyperglycemia have been reported (using continuous infusion at higher doses of omacetaxine).
- Active carcinoma requiring systemic chemotherapy or radiation therapy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Omacetaxine: Consolidation/Maintenance
|
Omacetaxine 1.25 mg/m² sub-cutaneously twice daily for 5 consecutive days every 28 (± 8) days for 3 cycles. Patients in continuous remission after 3 cycles of consolidation will receive maintenance omacetaxine 1.25 mg/m² twice daily for 3 days, every 28 days for up to 6 cycles
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease Status Assessment Prior to Each Consolidation Cycle
Time Frame: 14 days
|
Disease status will be assessed by a bone marrow aspirate and biopsy prior to each of 3 consolidation cycles (to ensure that patients are still in remission).
|
14 days
|
Assessment of Disease Status
Time Frame: 1 month
|
Bone marrow biopsy and aspirate will be obtained.
|
1 month
|
Bone Marrow Aspirate to Confirm Continuous Remission
Time Frame: 3 months
|
Bone marrow aspirate to confirm continuous remission will be obtained before starting maintenance and at 3 and 6 months from the start of maintenance.
|
3 months
|
Maintenance Toxicities
Time Frame: 24 weeks
|
Toxicities will be monitored by history, physical examination, and laboratory monitoring during maintenance.
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Consolidation Toxicities
Time Frame: 12 weeks
|
Toxicities will be monitored by history, physical examination, and laboratory monitoring (CBC, serum chemistries to include renal and liver function tests) obtained weekly during consolidation and monthly during maintenance according to standard of care (Appendices C and D).
Toxicity will be assessed according to the NCI Common Toxicity Criteria Version 4.0 (available at the NCI web site http://ctep.cancer.gov/reporting/ctc.html).
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Martha L. Arellano, MD, Emory University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2013
Primary Completion (ACTUAL)
July 1, 2018
Study Completion (ACTUAL)
July 1, 2018
Study Registration Dates
First Submitted
June 4, 2013
First Submitted That Met QC Criteria
June 6, 2013
First Posted (ESTIMATE)
June 10, 2013
Study Record Updates
Last Update Posted (ACTUAL)
September 24, 2019
Last Update Submitted That Met QC Criteria
September 5, 2019
Last Verified
September 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00057844
- Winship2176-11 (OTHER: Other)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myelogenous Leukemia (AML)
-
Eisai Inc.TerminatedPediatric Acute Myelogenous Leukemia (AML)United States, Canada, Australia
-
AbbVieGenentech, Inc.CompletedAcute Myeloid Leukemia | AML | Acute Myelogenous Leukemia
-
Maxinovel Pty., Ltd.RecruitingAcute Myelogenous Leukemia (AML)Australia
-
Merck Sharp & Dohme LLCTerminatedAcute Myelogenous Leukemia (AML)
-
Maxinovel Pty., Ltd.Recruiting
-
AbbVieGenentech, Inc.CompletedAML | Acute Myelogenous LeukemiaUnited States, Australia, Germany, Italy
-
Sidney Kimmel Cancer Center at Thomas Jefferson...University of PennsylvaniaCompleted
-
Eisai Inc.Withdrawn
-
Ascenta TherapeuticsThe Leukemia and Lymphoma SocietyTerminated
-
Beth Israel Deaconess Medical CenterDana-Farber Cancer Institute; National Institutes of Health (NIH); Medivation... and other collaboratorsActive, not recruitingAML | Acute Myelogenous LeukemiaUnited States
Clinical Trials on Omacetaxine
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedSolid Tumors | Hematologic MalignanciesNetherlands
-
ChemGenex PharmaceuticalsCompleted
-
Teva Branded Pharmaceutical Products R&D, Inc.Cephalon; ChemGenex PharmaceuticalsCompletedChronic Myeloid LeukemiaUnited States, Canada, France, Germany, Hungary, India, Italy, Poland, Singapore, United Kingdom
-
University of Illinois at ChicagoRecruitingRelapsed or Refractory Hematologic MalignanciesUnited States
-
M.D. Anderson Cancer CenterTeva Pharmaceuticals USACompleted
-
M.D. Anderson Cancer CenterTeva Pharmaceuticals USATerminated
-
Teva Branded Pharmaceutical Products R&D, Inc.Cephalon; ChemGenex PharmaceuticalsCompletedChronic Myeloid LeukemiaUnited States, Canada, France, Germany, Hungary, India, Italy, Poland, Singapore, United Kingdom
-
University of Colorado, DenverActive, not recruitingHigh Grade Myelodysplastic SyndromesUnited States
-
The University of Hong KongCompletedAML | FLT3-ITD MutationHong Kong